Bexicaserin for the treatment of seizures in developmental and epileptic encephalopathies: A phase 1b/2a trial ( <scp>PACIFIC</scp> )
Bexicaserin was well tolerated and associated with clinically relevant reductions in countable motor seizure frequencies in participants with a variety of DEEs. This novel trial design may expand treatment access to patients previously excluded from clinical trials.
Authors
- David G. Vossler (ORCID: https://orcid.org/0000-0003-4823-0537)
- Randall Kaye (ORCID: https://orcid.org/0000-0001-6703-7287)
- Dennis Dlugos (ORCID: https://orcid.org/0000-0003-3088-7645)
- Jacqueline A. French (ORCID: https://orcid.org/0000-0003-2242-8027)
- Ingrid Eileen Scheffer (ORCID: https://orcid.org/0000-0002-2311-2174)
- Shikha Polega
- Chad Orevillo
Institutions
- Royal Children's Hospital (AU)
- Children's Hospital of Philadelphia (US)
- Lundbeck (Denmark) (DK)
- The University of Melbourne (AU)
- University of Washington (US)
- Florey Institute of Neuroscience and Mental Health (AU)
- TiGenix (Spain) (ES)
- Murdoch Children's Research Institute (AU)
- Lundbeck (Italy) (IT)
- Austin Health (AU)
- New York University (US)
Publication Details
- Journal
- Epilepsia
- Published
- 2025-10-24
- DOI
- https://doi.org/10.1111/epi.18689
- Citations
- 2
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.94
Funders
- Zogenix
- H. Lundbeck A/S